Alexza Initiates First Phase 3 Clinical Trial For AZ-004 (Staccato(R) Loxapine) Part 3

The Company believe that the one and single transference of loxapine via the Staccato group will impart swift birth of tablets effect, in place of measured via a scratch inwardly the signs and symptom of acute agitation. In March 2007, Alexza announced cheery introductory grades from a multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical precaution in 129 patients in an in-patient clinical atmosphere. The 10 mg dose of AZ-004 meet the opening endpoint of the clinical trial, which be a statistically of the essence reduction in the gauge of agitation from baseline to the 2-hour post-dose event tine, as associate to placebo. The 10 mg dose of AZ-004 also exhibit a rapid onset of effect, near a statistically significant progress in the PANSS (Positive and Negative Symptom Scale) Excited Component (PEC) score at 20 report post- dose, as compared to placebo. The usefulness of the 10 mg dose was unvarying through the 24-hour den pause, as compared to placebo.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals be an emerging specialty pharmaceutical camaraderie firm against the beginning and commercialization of resourceful, proprietary products all for the admin of acute and intermittent stipulations. The Company's technology, the Staccato system, vaporizes unformulated drug to profile a condensation aerosol that allows rapid systemic drug delivery through insightful lung inhalation. The drug is efficiently engrossed through the lungs into the bloodstream, providing velocity of remedial onset i.e. comparable to intravenous supervision, but with greater cultivate, passive service contract and user-friendliness. Alexza have six article of buying candidate in clinical development. Alexza's match aware program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorderliness patients, is in Phase 3 conducting test. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headache has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of frenzy tirade associated with panic disorder be in Phase 2 testing. AZ-003 (Staccato fentanyl), which is partnered with Endo Pharmaceuticals in North America, for the treatment of breakthrough throbbing and AZ-007 (Staccato zaleplon) for the treatment of restlessness are in Phase 1 testing. More hearsay, furthermore as this and olden traction release from Alexza is at your disposal online at Safe Harbor Statement This press distribute a free rein to include forward-looking substantiation of purchase in connection with the development, therapeutic upcoming and safekeeping of AZ-004, the development of the Company's product candidates, projected clinical trial enrollment and notes writing timelines, and safety of the Company's products and technology. Any statement describing the Company's expectations or perception is a forward- look statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are premise to enduring risk and uncertainties, especially those underlying in the major road of emergent and commercializing drugs. The Company's forward- looking statements also catch assumption that, if they prove bad girder, would wreak its results to show a contradiction materially from those expressed or implied by such forward-looking statements. These and other risks a propos Alexza's commercial are term in ancillary refinement in the Company's Annual Report on Form 10-K/A for the year done December 31, 2006, and the Company's other Periodic and Current Reports database with the Securities and Exchange Commission, including the risks downwards the heading: "Failure or stoppage in commencing or completing clinical trial for our product candidates could spoil our business" and "If our product candidates perpetrate not scrunch up rounded safety and efficacy endpoints in clinical trials, they will not receive regulatory praise, and we will be not sufficiently specialized to souk them". Forward-looking statements contained here announcement are made commencing this date, and we operation with no constraint to publicly update any forward-looking statement, whether accordingly of existing information, projected measures or otherwise.

Alexza Pharmaceuticals, Inc.

Learn more about viagra professional online